Sinapsos Podcast | Oncology

E34   |  21 min   |   Latest   |  Publication Link

• Podcast based on: El-Haddad, G.; Gardner, L.; Kim, H.; Soares, H.P. Occurrence and Management of Acute, Subacute, and Delayed Toxicities in Patients with GEP-NETs Following Treatment with Radioligand Therapy. Cancers 2026, 18, 742. https://doi.org/10.3390/cancers18050742
  Type: Review  |  Publication date: 25 February 2026
  
  
• Summary: Radioligand therapy is a type of treatment being developed for many cancer types, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It uses specially designed drugs to deliver radiation directly to tumor cells within the body. Studies have shown that radioligand therapies can help some patients with GEP-NETs to live longer without disease progression. However, side effects have been reported in patients treated with radioligand therapies. Additionally, there is a risk of radiation exposure among people who come into contact with treated patients. In this article, we provide practical strategies to prevent and manage the side effects of radioligand therapy and to maintain radiation safety.
  
  
• Keywords: radioligand therapy; gastroenteropancreatic neuroendocrine tumors; adverse event; toxicity; management; radioactive contamination; radiation safety

License and disclaimer:
Original article © 2026 by the authors. Licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated audio adaptation of the article: the script and the voices are synthetic, changes were made, and the adaptation is not endorsed by the authors, the journal, or the publisher. It may contain errors or omissions, so consult the original publication before relying on any detail. It is for educational purposes only and is not medical advice. The creators accept no liability for any use of this content.